Bandaríkin - enska - NLM (National Library of Medicine)

taro pharmaceuticals u.s.a., inc. - levetiracetam (unii: 44yrr34555) (levetiracetam - unii:44yrr34555) - levetiracetam 250 mg - levetiracetam is indicated for the treatment of partial-onset seizures in patients 1 month of age and older. levetiracetam is indicated as adjunctive therapy for the treatment of myoclonic seizures in patients 12 years of age and older with juvenile myoclonic epilepsy. levetiracetam is indicated as adjunctive therapy for the treatment of primary generalized tonic-clonic seizures in patients 6 years of age and older with idiopathic generalized epilepsy. levetiracetam is contraindicated in patients with a hypersensitivity to levetiracetam. reactions have included anaphylaxis and angioedema [see warnings and precautions (5.4)] . pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antiepileptic drugs (aeds), including levetiracetam, during pregnancy. encourage women who are taking levetiracetam during pregnancy to enroll in the north american antiepileptic drug (naaed) pregnancy registry by calling 1-888-233-2334 or visiting http://www.aedpregna

Bandaríkin - enska - NLM (National Library of Medicine)

paddock laboratories, llc - sodium polystyrene sulfonate (unii: 1699g8679z) (polystyrene sulfonic acid - unii:70ko0r01ry) - sodium polystyrene sulfonate 15 g in 60 ml - sodium polystyrene sulfonate suspension, usp is contraindicated in the following conditions: patients with hypokalemia, patients with a history of hypersensitivity to polystyrene sulfonate resins, obstructive bowel disease, oral or rectal administration in neonates (particularly in premature infants), and in any post-operative patient until normal bowel function resumes (see precautions ).

Bandaríkin - enska - NLM (National Library of Medicine)

west-ward pharmaceuticals corp. - sodium polystyrene sulfonate (unii: 1699g8679z) (polystyrene sulfonic acid - unii:70ko0r01ry) - sodium polystyrene sulfonate 15 g in 60 ml - sodium polystyrene sulfonate is indicated for the treatment of hyperkalemia. sodium polystyrene sulfonate is contraindicated in the following conditions: patients with hypokalemia, patients with a history of hypersensitivity to polystyrene sulfonate resins, obstructive bowel disease, oral or rectal administration in neonates (see precautions ).

Malta - enska - Medicines Authority

ferring ireland limited united drug house, magna drive magna business park, citywest road dublin 24 , ireland - sodium picosulfate, magnesium oxide, light, citric acid, anhydrous - powder for oral solution - sodium picosulfate 10 mg magnesium oxide, light 3.5 g citric acid anhydrous 12 g - drugs for constipation

Ísrael - enska - Ministry of Health

tradis gat ltd - citric acid anhydrous; light magnesium oxide; sodium picosulfate - powder for solution - citric acid anhydrous 10.97 g; light magnesium oxide 3.5 g; sodium picosulfate 10 mg - sodium picosulfate, combinations - for bowel cleansing prior to any diagnostic procedures requiring a clean bowel e.g. colonoscopy or x-ray examination.

Írland - enska - HPRA (Health Products Regulatory Authority)

ssl international plc - magnesium oxidum leve aluminium hydroxide dimethicone 350 - oral suspension

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

wockhardt bio pty ltd - sodium valproate, quantity: 1000 mg - injection, solution - excipient ingredients: dibasic sodium phosphate dodecahydrate; monobasic sodium phosphate dihydrate; phosphoric acid; sodium hydroxide; water for injections - sodium valproate wockhardt is used for the treatment of patients with epilepsy or mania, who would normally be maintained on oral sodium valproate, and for whom oral therapy is temporarily not possible.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

wockhardt bio pty ltd - sodium valproate, quantity: 400 mg - injection, solution - excipient ingredients: dibasic sodium phosphate dodecahydrate; monobasic sodium phosphate dihydrate; phosphoric acid; sodium hydroxide; water for injections - sodium valproate wockhardt is used for the treatment of patients with epilepsy or mania, who would normally be maintained on oral sodium valproate, and for whom oral therapy is temporarily not possible.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

mega lifesciences (australia) pty ltd - citric acid, quantity: 590.388 mg/g; magnesium carbonate hydrate, quantity: 393.592 mg/g; sodium picosulfate, quantity: 500 microgram/g - oral liquid, powder for - excipient ingredients: colloidal anhydrous silica; sucralose; povidone; flavour - preparation for oral use for bowel cleansing prior to diagnostic medical or surgical procedures such as colonoscopy, other endoscopic examination, surgery, intravenous pyelograms (ivp), x-ray, bowel evacuation and barium enema, in adults and children 9 years of age and over.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - sodium valproate, quantity: 500 mg - tablet, enteric coated - excipient ingredients: triethyl citrate; citric acid; magnesium stearate; sodium starch glycollate; purified talc; povidone; microcrystalline cellulose; colloidal anhydrous silica; titanium dioxide; xanthan gum; polyvinyl alcohol; lecithin; polysorbate 80; purified water; methacrylic acid copolymer; sodium lauryl sulfate; indigo carmine; sunset yellow fcf; allura red ac; macrogol 3350 - epilepsy. primary generalised epilepsy (petit mal absences, various forms of myoclonic epilepsy and tonic-clonic grand mal seizures). partial (focal) epilepsy either alone or as adjuvant therapy.. mania. for the treatment of mania where other therapy has proved inadequate or is inappropriate.